CW June 2003
Volume 12Issue Number 6 June 2003 ISSN 10593802 Monoclonal Antibody Trastuzumab does not Cross Blood-Brain BarrierWomen with HER-2/neu receptor-positive metastatic breast cancer respond very well to trastuzumab-based therapy. Trastuzumab is a monoclonal antibody directed against HER-2/neu receptors. However, patients treated with this antibody have a high risk of developing brain metastasis. One reason may be poor penetration of this antibody to cerebrospinal fluid.
Go to Previous Page Go to Next Page Source & Additional Reading J. Bendell et al., Cancer, June 15. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW June 2003Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
